Brief: Endo Provides Top-Line Results From Phase 2 Study Of Collagenase Clostridium Histolyticum In Participants With Adhesive Capsulitis Of The Shoulder
01/07/2022 12:34
July 1 (Reuters) - Endo International PLC ENDP.O :
* ENDO PROVIDES TOP-LINE RESULTS FROM PHASE 2 STUDY OF
COLLAGENASE
CLOSTRIDIUM HISTOLYTICUM (CCH) IN PARTICIPANTS WITH ADHESIVE
CAPSULITIS OF THE SHOULDER
* ENDO INTERNATIONAL PLC - SAFETY PROFILE OF CCH IN PHASE 2
STUDY
WAS CONSISTENT WITH KNOWN SAFETY PROFILE FROM OTHER STUDIES
* ENDO - MOST TREATMENT-EMERGENT ADVERSE EVENTS WERE OF MILD
TO
MODERATE SEVERITY IN STUDY
* ENDO INTERNATIONAL - DIFFERENCE IN PARTICIPANTS RECEIVING
3
DOSES OF CCH IN STUFY VERSUS PARTICIPANTS GETTING PLACEBO WAS
NOT STATISTICALLY SIGNIFICANT
Source text for Eikon: ID:nPn1YT1XVa
Further company coverage: ENDP.O
Recent news on Endo International
See all newsBrief: Endo International PLC Files For Offering Of Up To 31.1 Million Common Shares By The Selling Stockholders - SEC Filing
Brief: Par Pharmaceutical Issues Voluntary Nationwide Recall Of Seven Lots Of Treprostinil Injection
Brief: Endo International Says Wholly-Owned Subsidiary Endo Finance Priced Its $1.5 Bln Senior Secured Seven-Year Term Loan
Brief: Endo, Inc. Announces Pricing Of $1 Bln Of Senior Secured Notes
Brief: Endo Announces Proposed Private Offering Of Senior Secured Notes